Atossa Genetics (NASDAQ:ATOS) Stock Price Crosses Below 200-Day Moving Average – Should You Sell?

Atossa Genetics Inc. (NASDAQ:ATOS) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.59 and traded as low as $5.10. Atossa Genetics shares last traded at $5.15, with a volume of 54,707 shares trading hands.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Ascendiant Capital Markets boosted their target price on shares of Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 8th. HC Wainwright boosted their target price on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $68.33.

Atossa Genetics Trading Down 3.9%

The company has a market cap of $44.34 million, a PE ratio of -1.43 and a beta of 1.34. The firm’s fifty day moving average is $5.18 and its 200 day moving average is $9.59.

Institutional Investors Weigh In On Atossa Genetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. Bank of America Corp DE increased its holdings in Atossa Genetics by 51.3% in the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after acquiring an additional 37,809 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in Atossa Genetics by 357.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after acquiring an additional 325,340 shares in the last quarter. Jane Street Group LLC purchased a new stake in Atossa Genetics in the 2nd quarter worth $381,000. Ameriprise Financial Inc. purchased a new stake in Atossa Genetics in the 2nd quarter worth $2,468,000. Finally, Hudson Bay Capital Management LP purchased a new stake in Atossa Genetics in the 2nd quarter worth $26,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.